Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-DEP and PD-1 Antibody in R/R EBV-HLH
NCT05315336Phase 3Not yet recruiting
- Sponsor
- Beijing Friendship Hospital
- Start
- Jun 2022
- Primary completion
- Jun 2025
- Countries
- 1
01
Overview
Phase 3, open-label trial in Epstein-Barr Virus-associated Hemophagocytic Lymphohistiocytosis (EBV-HLH), sponsored by Beijing Friendship Hospital. Primary endpoint: Evaluation of treatment response at 8 weeks. Planned start Jun 2022; status: not yet recruiting.
02
Conditions
Epstein-Barr Virus-associated Hemophagocytic Lymphohistiocytosis (EBV-HLH)
Beyond the preview
Go deeper on NCT05315336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05315336.